1. Introduction {#sec1-cancers-12-00994}
===============

Brain tumor-related epilepsy (BTE) is a common symptom of patients with intracranial gliomas and occurs in about 50% of high-grade and up to 100% of low-grade glioma patients \[[@B1-cancers-12-00994],[@B2-cancers-12-00994],[@B3-cancers-12-00994],[@B4-cancers-12-00994],[@B5-cancers-12-00994]\]. Many studies investigated the pathophysiological mechanisms of BTE and its risk factors \[[@B6-cancers-12-00994],[@B7-cancers-12-00994]\]. Mutation of the isocitrate dehydrogenase 1/2 \[[@B8-cancers-12-00994]\] (IDH1/2-) gene was shown to correlate with seizures in low-grade gliomas due to the production of D-2-hydroxyglutarate which is similar to glutamate, an excitatory neurotransmitter that initiates NMDA-receptor related pathways \[[@B1-cancers-12-00994],[@B9-cancers-12-00994],[@B10-cancers-12-00994],[@B11-cancers-12-00994],[@B12-cancers-12-00994]\]. Many other factors are involved in the pathophysiology of BTE such as ionic changes, GABAergic pathways, hypoxia and inflammatory changes \[[@B12-cancers-12-00994]\]. The tumor location and the type of the tumor play an important role, slowly growing tumors have a higher risk of seizures \[[@B4-cancers-12-00994],[@B12-cancers-12-00994]\]. Seizure as first manifestation of the tumor was also shown to be associated with a better prognosis \[[@B5-cancers-12-00994]\]. Also the peritumoral region has attracted attention in the pathophysiology of BTE \[[@B13-cancers-12-00994],[@B14-cancers-12-00994],[@B15-cancers-12-00994],[@B16-cancers-12-00994]\]. Studies showed that high-grade glioma patients with smaller preoperative tumor size significantly more often presented with seizures, whereas for low-grade gliomas contradicting results were shown \[[@B17-cancers-12-00994],[@B18-cancers-12-00994]\].

Diffusion tensor imaging (DTI) is routinely used in preoperative glioma imaging and provides an insight into the microstructure of tumors and brain tissue \[[@B19-cancers-12-00994]\]. The main quantitative values assessed via DTI are the apparent diffusion coefficient (ADC) and fractional anisotropy (FA). Studies showed that not only the contrast-enhancing tumor but also the non-enhancing peritumoral region demonstrate differences in the microstructure measured especially by FA \[[@B20-cancers-12-00994],[@B21-cancers-12-00994],[@B22-cancers-12-00994]\].

To our knowledge, there are no studies that assessed the relationship between preoperative seizures and FA/ADC values in glioblastoma patients.

We therefore hypothesize that glioblastoma causing preoperative seizures differ from glioblastoma causing no preoperative seizures in size, location and microstructure measured by DTI.

2. Methods {#sec2-cancers-12-00994}
==========

This retrospective single-center non-interventional study was approved by the local ethics committee (5625-12) at the Klinikum rechts der Isar of the Technical University of Munich, Germany and performed in accordance with the ethical standards of the 1964 Declaration of Helsinki and its later amendments \[[@B23-cancers-12-00994]\].

2.1. Patient Population {#sec2dot1-cancers-12-00994}
-----------------------

From the local database 160 consecutive patients with surgery for a newly diagnosed glioblastoma (GB) (WHO IV) between 01/2010 and 12/2015 were included in this study. They were selected from a collective of 260 patients choosing those with completely recorded clinical data, especially concerning epilepsy data, as well as complete preoperative in-house imaging protocol included high-resolution magnetic resonance imaging (T1-weighted imaging after contrast agent, Fluid-Attenuated-Inversion-Recovery (FLAIR) images and diffusion tensor imaging (DTI)). Only patients with first diagnosis of glioblastoma in a preoperative stage, not having received any chemotherapy or radiotherapy before date of image acquisition, were selected. The occurrence of seizure as initial tumor manifestation was recorded by qualified neurosurgeons. Isocitrate-dehydrogenase 1 (IDH1)-mutation status was assessed in 109/160 patients in the local department of neuropathology via immunostaining against the R132H mutation in all patients.

2.2. MR Imaging {#sec2dot2-cancers-12-00994}
---------------

MRI scans were performed on a 3 Tesla (T) MRI scanner, either Philips Achieva, Philips Ingenia (Philips Medical Systems, The Netherlands B.V.) or Siemens Verio (Siemens Healthcare, Erlangen, Germany). All patients had FLAIR-images, high-resolution T1-weighted (w) images with and without contrast agent (MPRage, 1 mm isotropic) and Diffusion Tensor Imaging (DTI). DTI sequence either comprised 6 diffusion directions (b value 800 s/mm^2^, TR/TE 7665/55 ms, resolution 2 × 2 × 2 mm) or 15 diffusion directions (b value 800 s/mm^2^, TR/TE 10728/55 ms, resolution 2 × 2 × 2 mm) or 15 diffusion directions (b1000, TR/TE 7665/55 ms, resolution 2 × 2 × 2 mm). The contrast agent Magnograf® was administered intravenously by a standardized protocol (0.2 mL/kg, 0.5--1 mL/sec), using a MR compatible contrast medium injection system (Spectris Solaris EP, Siemens Medical, Erlangen, Germany).

2.3. Image Analysis {#sec2dot3-cancers-12-00994}
-------------------

Image analysis was supervised by two neuroradiologists (BW, 7 years of experience and SB, 7 years of experience) blinded to the clinical data. Image pre-processing encompassed N4 bias-field correction and linear co-registration using the open-source ANTs packages (<https://stnava.github.io/ANTs/>) \[[@B24-cancers-12-00994]\]. DTI processing was done with DiPy (<https://nipy.org/dipy/>) \[[@B25-cancers-12-00994]\], including affine registration of diffusion-weighted images to the b0 image and appropriate vector rotation and non-linear estimation of the diffusion tensor. Semi-automatic segmentation of tumors in two mutually exclusive areas (contrast-enhancing and FLAIR-hyperintense tumor) was performed using a generative probabilistic model \[[@B26-cancers-12-00994]\]. Lesion-filled T1 images were deformably registered (SyN) to the SRI24 atlas \[[@B27-cancers-12-00994]\]. Resulting segmentations and atlas images were checked manually prior to analysis with the freely available software ITK-SNAP ([www.itksnap.org](www.itksnap.org)) \[[@B28-cancers-12-00994]\]. From the co-registered FA and ADC maps, first-order statistics were automatically calculated using the PyRadiomics package (<https://pyradiomics.readthedocs.io/>) \[[@B29-cancers-12-00994]\] in both contrast-enhancing and FLAIR-hyperintense tumor areas. Volume information and atlas locations were collected for both areas ([Figure 1](#cancers-12-00994-f001){ref-type="fig"}). Tumor size was calculated by counting voxels (each voxel with a size of 1 × 1 × 1 mm) and shown as mm^3^. For atlas localization, the extent of the entire mass was analyzed. All scripts are available upon request from B.W.

2.4. Statistics {#sec2dot4-cancers-12-00994}
---------------

Statistical analysis including descriptive data analysis was performed using IBM SPSS Statistics version 24.0 (SPSS Inc., IBM Corp., Armonk, NY, USA), Python version 3.6 (<https://www.python.org/>) and R version 3.5 (<https://www.r-project.org/>). To compare first-order statistics in patients with and without seizures and account for multiple testing, random label permutations (with 1000 iterations) were performed as described previously \[[@B30-cancers-12-00994]\]. Wilcoxon tests were performed for correlations of histogram analyses and tumor location (location of the tumor in a brain region that was significantly associated with seizures in this cohort vs. location of the tumor in another region), Pearson correlation analyses were performed to analyze the influence of tumor volume on histogram analyses.

A difference with an error probability of less than 0.05 was considered as statistically significant.

3. Results {#sec3-cancers-12-00994}
==========

3.1. Patients' and Tumor Characteristics {#sec3dot1-cancers-12-00994}
----------------------------------------

The study population comprises 160 consecutive patients (90 male, mean age 64y +/- 13.9) with initial diagnosis of a glioblastoma (WHO IV) ([Table 1](#cancers-12-00994-t001){ref-type="table"}). 60/160 patients presented with preoperative seizures. 87/160 tumors showed infiltration of the frontal lobe, 93/160 tumors infiltrated the temporal lobe. Infiltration of the parietal lobe was shown in 57/160 cases, of the occipital lobe in 37/160 cases. 90/160 tumors showed infiltration of the insular region, 51/160 tumors of the hippocampus. The brainstem was infiltrated in 13/160 cases, the cerebellum in 4/160 cases.

3.2. Tumor Size and Location {#sec3dot2-cancers-12-00994}
----------------------------

Patients with seizures showed significantly smaller tumors (contrast enhancing tumor) (adj. *p* = 0.029) than patients without preoperative seizures. FLAIR volume did not significantly differ between patients with and without preoperative seizures (adj. *p* = 0.725) ([Table 2](#cancers-12-00994-t002){ref-type="table"}).

Patients with tumor location in the right cingulate gyrus (adj. *p* = 0.048) and in the right caudate nucleus (adj. *p* = 0.009) showed significantly less preoperative seizures ([Table 3](#cancers-12-00994-t003){ref-type="table"}). Patients with tumors in the limbic system (including parahippocampal and hippocampal gyrus and cingulate gyrus) also showed significantly less preoperative seizures (*p* = 0.030) All other tumor locations were not associated with the occurrence of preoperative seizures. [Figure 2](#cancers-12-00994-f002){ref-type="fig"} shows examples of a patient with a small tumor in the left frontal lobe presenting with seizures (A,B) and a patient with a large tumor in the right cingulate gyrus presenting without preoperative seizures (C,D).

3.3. Histogram Analyses {#sec3dot3-cancers-12-00994}
-----------------------

Histogram analyses of fractional anisotropy (FA) in the contrast enhancing tumor part significantly differed between patients with and without preoperative seizures. The following features showed significant differences: Energy (adj. *p* = 0.017), Entropy (adj. *p* = 0.043), Interquartile Range (adj. *p* = 0.013), Maximum (adj. *p* = 0.043), Mean Absolute Deviation (adj. *p* = 0.017), Range (adj. *p* = 0.025), Total Energy (adj. *p* = 0.017), Variance (adj. *p* = 0.039) ([Figure 3](#cancers-12-00994-f003){ref-type="fig"}). All features were significantly smaller in patients presenting with seizures.

No significant differences were observed between histogram analyses of ADC in the contrast enhancing tumor part and of FA and ADC in the FLAIR-hyperintense part ([Table S1](#app1-cancers-12-00994){ref-type="app"}).

Analyses for correlations between tumor location and FA histogram analyses showed no significant differences ([Figure S1](#app1-cancers-12-00994){ref-type="app"}).

Tumor size showed significant positive correlations to the following FA histogram features: Energy, Entropy, Maximum, Range und Total Energy. No significant correlations were observed between tumor size and the features Interquartile Range, Variance and Mean Absolute Deviation ([Figure S1](#app1-cancers-12-00994){ref-type="app"}). Significant correlations were shown between the FA features that are independent of tumor size: Interquartile Range/Variance: *r* = 0.927, *p* \< 0.001; Interquartile Range/Mean Absolute Deviation: *r* = 0.966, *p* \< 0.001, Mean Absolute Deviation/Variance: *r* = 0.963, *p* \< 0.001.

4. Discussion {#sec4-cancers-12-00994}
=============

Glioblastoma patients with preoperative seizures show significantly smaller tumors. Tumor location in the right cingulate gyrus and in the right caudate nucleus were associated with less preoperative seizures whereas infiltration of the hippocampus and the insula did not appear to promote epileptogenesis.

Tumors with and without preoperative seizures differed in histogram analyses of FA in the contrast enhancing tumor -- with smaller values in the features Interquartile Range, Mean Absolute Deviation and Variance after consideration of tumor size. As glioma patients with preoperative seizures were shown to have a better prognosis \[[@B31-cancers-12-00994]\], this might be reflected by differences in the microstructure.

Brain tumor-related epilepsy was shown to mainly occur in low-grade glioma patients, whereas glioblastoma patients more often present with other symptoms such as neurologic deficits or headache due to the mass effect \[[@B4-cancers-12-00994],[@B5-cancers-12-00994],[@B7-cancers-12-00994],[@B17-cancers-12-00994]\]. As seizures were shown to be associated with improved survival in high-grade glioma \[[@B31-cancers-12-00994]\], it is of high importance to characterize the exact pathomechanisms causing seizures in glioma patients to develop new therapy strategies. Many studies investigated the pathomechanisms for brain tumor-related seizures \[[@B1-cancers-12-00994],[@B9-cancers-12-00994],[@B10-cancers-12-00994],[@B11-cancers-12-00994],[@B13-cancers-12-00994],[@B16-cancers-12-00994],[@B18-cancers-12-00994],[@B31-cancers-12-00994]\]. There are two main hypotheses: First, the mechanical compression of surrounding brain structures by the tumor mass might cause seizures which is supported by the findings that gross-total tumor resection is associated with seizure-control \[[@B31-cancers-12-00994],[@B32-cancers-12-00994]\]. Second, the tumor excretes epileptogenic factors such as glutamate or causes altered gene expression in the peritumoral region which results in seizures \[[@B31-cancers-12-00994],[@B33-cancers-12-00994],[@B34-cancers-12-00994],[@B35-cancers-12-00994]\].

The main results of this study are that preoperative tumor volume of the contrast enhancing tumor (not the FLAIR-hyperintense edema) shows a significant correlation to seizures. This is in common with a previous study by Skardelly et al. that showed a tumor volume \<64 cm^3^ as a main risk factor for the development of preoperative seizures \[[@B18-cancers-12-00994]\]. Another study showed that this association was only found in high-grade gliomas, but not in low-grade gliomas where an inverse association between tumor volume and seizures was observed \[[@B17-cancers-12-00994]\]. The mentioned study by Skardelly et al. reported a large population of 242 glioblastoma patients. More rapidly growing tumors might more often be associated with other symptoms such as hemiparesis, aphasia or headache due to the mass effect \[[@B17-cancers-12-00994]\]. In contrast, small tumors are lacking this space-consuming effect. These results would suggest that smaller tumors might have a higher epileptogenic level than larger high-grade tumors. A possible pathomechanism might be that these smaller tumors excrete epileptogenic factors or perform changes in the peritumoral region as it was discussed in previous studies \[[@B9-cancers-12-00994],[@B33-cancers-12-00994],[@B34-cancers-12-00994]\].

At this point a parallel to low grade gliomas, especially to the larger ones with a relevant surround reaction and higher level of aggressiveness and growth rate as in small ones, could be seen, that consequently also show a higher epileptogenic potential \[[@B17-cancers-12-00994]\].

It remains to be seen if these small high-grade gliomas are at an early stage of growth with an early diagnosis due to seizures as their primary symptom or if they represent a slowly growing, overall less aggressive tumor type with a higher epileptogenic potential. Further studies that investigate the exact pathophysiologic mechanisms of tumor growth and seizures will have to be performed to better characterize these tumor types.

In the present study, glioblastomas without seizures showed a preference towards the right cingulate gyrus and the right caudate nucleus. These findings are in common with a previous study by Lee JW et al. \[[@B17-cancers-12-00994]\]. According to this study high grade gliomas presenting with neurologic symptoms instead of seizures were more likely to occur in the pericallosal region \[[@B17-cancers-12-00994]\]. Interestingly other than previous studies, we found no significant associations between location in the left hemisphere and infiltration of the hippocampus was associated with preoperative seizure as shown in previous studies \[[@B18-cancers-12-00994],[@B31-cancers-12-00994],[@B32-cancers-12-00994]\]. Main explanation for this finding might be that the cited previous studies mainly assessed low-grade gliomas whereas this study only investigated glioblastoma patients only.

Histogram analyses of FA in the contrast enhancing tumor significantly differed between patients with and without seizures suggesting that there are microstructural differences in this tumor area.

Previous studies analyzed FA values in the CE tumor and showed that GB have higher FA values than brain metastases \[[@B36-cancers-12-00994],[@B37-cancers-12-00994],[@B38-cancers-12-00994],[@B39-cancers-12-00994]\]. Higher FA values in the CE tumor were explained as an overproduction of extracellular matrix by glioblastoma cells that accumulate in the CE tumor area \[[@B37-cancers-12-00994],[@B39-cancers-12-00994],[@B40-cancers-12-00994],[@B41-cancers-12-00994]\]. These results might suggest that especially the contrast enhancing tumor area attracts attention for further studies concerning the pathophysiology of preoperative seizures.

Tumors presenting with seizures showed significantly lower values in the features Energy, Entropy, Maximum, Range, Total Energy, Interquartile Range, Mean Absolute Deviation and Variance. The features Energy, Entropy, Maximum, Range and Total Energy were also associated with tumor size, therefore this difference might be explained as tumors presenting with seizures are significantly smaller. Interquartile Range, Mean Absolute Deviation and Variance however, were independently smaller in tumors presenting with seizures. These three FA measures-Interquartile Range, Mean Absolute Deviation and Variance--are all associated with FA variability and are highly correlated with each other.

These results might suggest that tumors presenting with seizures are more homogenous and show a growth similar to low-grade tumors (that also present with seizures more often than high-grade tumors). On the other hand, tumors presenting without seizures might show a more inhomogenous/aggressive growth.

Main limitation of this study is its retrospective design. The semiautomatic segmentation is a reliable tool for measurement of tumor volume but also associated with precision errors \[[@B42-cancers-12-00994]\]. However, by now this might be considered state of the art and both, the volumetric measurements and the qualitative data analysis, were performed blinded to the clinical data to reduce this bias. Another limitation is the fact that the results were not validated in an independent cohort. Therefore, further studies are necessary to confirm the results of this study.

5. Conclusions {#sec5-cancers-12-00994}
==============

In glioblastoma patients, preoperative seizures were associated with significantly smaller contrast enhancing tumor volumes. Tumor location in the right cingulate gyrus and caudate nucleus were associated with less preoperative seizures. Significant differences in histogram analyses of FA in the contrast enhancing tumor part were observed suggesting that there are microstructural differences between these tumors. As glioblastomas with preoperative seizures are associated with an improved survival it is important to investigate the exact pathomechanisms causing brain-tumor related epilepsy.

The following are available online at <https://www.mdpi.com/2072-6694/12/4/994/s1>, Figure S1: Box plots for FA first order features in tumors in epilepsy location/different location, Table S1: First order features.
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cancers-12-00994-t001_Table 1

###### 

Baseline patient and tumor characteristics.

  Age                     64 Years (+/-13.9)
  ----------------------- --------------------
  Sex, male               90/160
  Preoperative seizure    60/160
  Tumor infiltration of   
  \- frontal lobe         87/160
  \- temporal lobe        93/160
  \- parietal lobe        57/160
  \- occipital lobe       37/160
  \- insula               90/160
  \- hippocampus          51/160
  \- cerebellum           4/160
  \- brainstem            13/160
  Hemisphere              
  \- right                74/160
  \- left                 64/160
  \- both                 22/160
  IDH1-wildtype           108/109

Normally distributed variables shown as mean +/- standard deviation.

cancers-12-00994-t002_Table 2

###### 

Tumor size.

  MR Sequence   Seizure                            No Seizure                          adj. *p*-Value
  ------------- ---------------------------------- ----------------------------------- ----------------
  FLAIR         48884.4 mm^3^ (31830.9--97074.7)   85391.7 mm^3^ (54260.2--124244.1)   0.725
  CET\*         8434.9 mm^3^ (3604.9--17662.9)     14805.7 mm^3^ (8196.8--26347.5)     0.029

Data shown as median (interquartile range); CET: contrast enhancing tumor, FLAIR: fluid-attenuated inversion recovery; \* *p* \< 0.05.

cancers-12-00994-t003_Table 3

###### 

Tumor location and seizures.

  Location                            Seizure (*n* = 60)   No Seizure (*n* = 100)   Odds Ratio   Perm. *p*-Value
  ----------------------------------- -------------------- ------------------------ ------------ -----------------
  Left superior frontal gyrus         17                   38                       0.645        0.857
  Right superior frontal gyrus        19                   43                       0.614        0.140
  Left middle frontal gyrus           16                   29                       0.890        1
  Right middle frontal gyrus          15                   41                       0.480        0.172
  Left inferior frontal gyrus         16                   27                       0.983        1
  Right inferior frontal gyrus        13                   37                       0.471        0.248
  Left precentral gyrus               19                   30                       1.081        1
  Right precentral gyrus              18                   50                       0.429        0.091
  Left middle orbitofrontal gyrus     9                    20                       0.706        1
  Right middle orbitofrontal gyrus    4                    25                       0.214        0.064
  Left lateral orbitofrontal gyrus    9                    19                       0.752        1
  Right lateral orbitofrontal gyrus   6                    27                       0.300        0.214
  Left gyrus rectus                   2                    12                       0.253        1
  Right gyrus rectus                  4                    11                       0.578        0.783
  Left postcentral gyrus              15                   21                       1.254        0.999
  Right postcentral gyrus             16                   46                       0.427        0.200
  Left superior parietal gyrus        9                    14                       1.084        1
  Right superior parietal gyrus       15                   29                       0.816        1
  Left supramarginal gyrus            9                    12                       1.294        1
  Right supramarginal gyrus           10                   30                       0.467        0.072
  Left angular gyrus                  14                   16                       1.598        0.991
  Right angular gyrus                 12                   26                       0.712        0.935
  Left precuneus                      9                    13                       1.181        1
  Right precuneus                     11                   26                       0.639        1
  Left superior occipital gyrus       6                    7                        1.476        1
  Right superior occipital gyrus      8                    21                       0.579        0.873
  Left middle occipital gyrus         9                    9                        1.784        0.449
  Right middle occipital gyrus        10                   21                       0.752        1
  Left inferior occipital gyrus       7                    10                       1.189        1
  Right inferior occipital gyrus      8                    10                       1.385        1
  Left cuneus                         8                    8                        1.769        0.995
  Right cuneus                        7                    13                       0.884        1
  Left superior temporal gyrus        24                   31                       1.484        0.943
  Right superior temporal gyrus       18                   46                       0.503        0.266
  Left middle temporal gyrus          21                   27                       1.456        0.999
  Right middle temporal gyrus         14                   39                       0.476        0.125
  Left inferior temporal gyrus        20                   26                       1.423        0.998
  Right inferior temporal gyrus       15                   26                       0.949        1
  Left parahippocampal gyrus          19                   27                       1.253        1
  Right parahippocampal gyrus         14                   31                       0.677        0968
  Left lingual gyrus                  11                   19                       0.957        1
  Right lingual gyrus                 12                   25                       0.750        0.995
  Left fusiform gyrus                 17                   24                       1.252        1
  Right fusiform gyrus                13                   30                       0.645        0.999
  Left insular cortex                 18                   32                       0.911        1
  Right insular cortex                18                   46                       0.503        0.266
  Left cingulate gyrus                18                   42                       0.592        0.877
  *Right cingulate gyrus*             *19*                 *49*                     *0.482*      *0.048*
  Left caudate                        19                   35                       0.861        1
  *Right caudate*                     *14*                 *45*                     *0.372*      *0.009*
  Left putamen                        20                   36                       0.889        1
  Right putamen                       19                   49                       0.482        0.187
  Left hippocampus                    18                   27                       1.159        1
  Right hippocampus                   15                   36                       0.593        0.476
  cerebellum                          9                    15                       1.000        1
  brainstem                           12                   29                       0.612        1

[^1]: These authors contributed equally to this paper.
